

OncoMed Pharmaceuticals Inc  
Form SC 13G  
August 24, 2016

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**

**(Amendment No. \_\_)**

**ONCOMED PHARMACEUTICALS, INC.**

**(Name of Issuer)**

**Common Stock**

**(Title of Class of Securities)**

**68234X102**

**(CUSIP Number)**

**August 23, 2016**

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 68234X102

Names of reporting persons.

1.

Celgene Corporation

Check the appropriate box if a member of a group\*

2. (a) " (b) "

SEC use only

3.

Citizenship or place of organization

4.

Delaware

Sole voting power

Number of 5.

shares 2,970,588 shares of Common Stock of the Issuer  
Shared voting power

beneficially 6.

owned by 0  
each Sole dispositive power

reporting 7.

person 2,970,588 shares of Common Stock of the Issuer  
Shared dispositive power

with 8.

0

Aggregate amount beneficially owned by each reporting person

9.

2,970,588 shares of Common Stock of the Issuer

Edgar Filing: OncoMed Pharmaceuticals Inc - Form SC 13G

Check box if the aggregate amount in Row (9) excludes certain shares\* ..

10.

Percent of class represented by amount in Row (9)

11.

8.1%

Type of reporting person\*

12.

CO

\*SEE INSTRUCTIONS BEFORE FILLING OUT.

Name of Issuer:

**Item 1(a).**

OncoMed Pharmaceuticals, Inc.

Address of Issuer's Principal Executive Offices:

**Item 1(b).**

800 Chesapeake Drive

Redwood City, California 94063

Name of Person Filing:

**Item 2(a).**

Celgene Corporation

Address of Principal Business Office or, if none, Residence:

**Item 2(b).**

86 Morris Avenue

Summit, New Jersey 07901

Citizenship:

**Item 2(c).**

Delaware, U.S.A.

Title of Class of Securities:

**Item 2(d).**

Common Stock, par value \$0.001

CUSIP Number:

**Item 2(e).**

68234X102

**Item 3.**

**If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:**

- (a)  Broker or dealer registered under section 15 of the Exchange Act.
- (b)  Bank as defined in section 3(a)(6) of the Exchange Act.
- (c)  Insurance company as defined in section 3(a)(19) of the Exchange Act.
- (d)  Investment company registered under section 8 of the Investment Company Act.
- (e)  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
- (f)  An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
- (g)  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act.
- (j)  A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
- (k)  Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

Not applicable.

**Item 4. Ownership.**

Amount beneficially owned:

(a)

2,970,588 shares of Common Stock of the Issuer

Percent of class:

(b)

8.1%. Such percentage is based upon 36,709,393 shares of Common Stock of the Issuer outstanding as of August 23, 2016.

(c) Number of shares as to which such person has:

Sole power to vote or to direct the vote:

(i)

2,970,588

Shared power to vote or to direct vote:

(ii)

0

Sole power to dispose or to direct the disposition of:

(iii)

2,970,588

Shared power to dispose or to direct the disposition of:

(iv)

0

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following "

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7.**

**Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

**Item 10. Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.



**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 23, 2016

**CELGENE CORPORATION**

By: /s/ Peter N. Kellogg  
Peter N. Kellogg  
Executive Vice President and Chief Financial Officer